Immunomedics (NASDAQ: IMMU) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Immunomedics to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, risk, dividends, profitability and earnings.
Volatility & Risk
Immunomedics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Immunomedics’ peers have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.
Valuation & Earnings
This table compares Immunomedics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Immunomedics||$3.09 million||-$153.20 million||-6.92|
|Immunomedics Competitors||$217.40 million||-$39.57 million||-17.71|
Immunomedics’ peers have higher revenue and earnings than Immunomedics. Immunomedics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations for Immunomedics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunomedics currently has a consensus target price of $15.50, indicating a potential upside of 0.00%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.56%. Given Immunomedics’ peers higher probable upside, analysts clearly believe Immunomedics has less favorable growth aspects than its peers.
This table compares Immunomedics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
76.3% of Immunomedics shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.6% of Immunomedics shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immunomedics peers beat Immunomedics on 8 of the 13 factors compared.
Immunomedics Company Profile
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.